-
Part 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
Part 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
Part 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
Part 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
Part 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
Part 2 | Session 5 SOUL: Semaglutide in Patients with T2D
-
Part 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
Part 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
Part 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
Part 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
Part 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
Part 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
Part 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
Part 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
Join renowned interventional cardiologists Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) for an exclusive preview of ACC.25's most significant late-breaking science.
This episode of View from the Thoraxcenter delivers authoritative analysis of pivotal cardiovascular trials set to revolutionize clinical practice and research. Elevate your conference experience with this essential preview, where Prof Van Mieghem and Dr Daemen provide evidence-based insights that expertly contextualize each trial within today's cardiovascular landscape. Their seasoned perspective offers valuable clarity on how these groundbreaking findings will directly influence patient care protocols and shape the future of cardiology.
Trials covered include:
PROTECTED-TAVI
Evolut Low Risk: 5 Year Outcomes
TRILUMINATE
FLAVOUR II
FAME 3: 5 Year Outcomes
ECLIPSE
ALTSHOCK II
Comparison of DAPT Duration After Stenting in High and Low Bleeding Risk Populations
Clopidogrel Vs Aspirin Post-PCI in Patients with High Ischaemic Risk
DapaTAVI
FAIR-HF2
FRESH-UP
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Faculty Biographies

Joost Daemen
Interventional Cardiologist
Dr Joost Daemen, MD, PhD is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center, Rotterdam in 2005 and did 2 years of internal medicine training and 4 years of general cardiology training at the Thoraxcenter, Rotterdam.
Dr Daemen is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.

Nicolas M Van Mieghem
Medical Director
Prof Nicolas Maria Van Mieghem is an Interventional cardiologist at Thoraxcenter, Erasmus MC, Rotterdam, NL decided to pursue a career that would help others. “I enjoy the feeling of being able to help someone or do something important for them". His father was a general cardiologist and one of his biggest influences early in his career.
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
His current research focuses on cerebral embolic protection during TAVI and the search for improved…
Comments